

RESPONSE

HONORABLE SIR:

Responsive to the official communication of August 12, 2002, Applicant submits the following Response.

It is not believed that extensions of time are required beyond those which may otherwise be provided for in documents accompanying this Response. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned for under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account 20-0823.

IN THE CLAIMS:

The claims have been amended as indicated in the marked up claims below. As required, a clean version of the amended claims is attached.

11. (Amended) The isolated and purified nucleic acid molecule or nucleic acid molecule complementary thereto of claim 10 wherein the nucleotide sequence or the fragment of said nucleotide sequence or complement thereto specifically hybridizes to [SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:194, SEQ ID NO:195,] SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, or SEQ ID NO:202.

12. (Amended) The isolated and purified nucleic acid molecule or nucleic acid molecule complementary thereto of claim 11 comprising [SEQ ID NO:183, SEQ ID NO:194,] SEQ ID NO:199 or SEQ ID NO:201.

15. (Amended) An isolated and purified nucleic acid molecule comprising:

(a) a pre-pro persephin nucleotide sequence as set forth in [SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191,] SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206 or a polynucleotide that specifically hybridizes to